Twist and MediSix link up on T-cell therapies development

8 April 2022

Twist Bioscience (Nasdaq: TWST) and MediSix Therapeutics have announced a collaboration to discover novel antibodies against five undisclosed targets.

Under the terms of the collaboration, Twist will leverage its proprietary Library of Libraries to discover five novel antibodies directed against MediSix’s targets. MediSix will use its unique platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune diseases without any CAR T-cell fractricide.

Twist will receive an undisclosed upfront payment and will be eligible to receive success-based clinical and regulatory milestone payments, as well as royalties on product sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK